PT575054E - Derivados de proteina c - Google Patents

Derivados de proteina c

Info

Publication number
PT575054E
PT575054E PT93303894T PT93303894T PT575054E PT 575054 E PT575054 E PT 575054E PT 93303894 T PT93303894 T PT 93303894T PT 93303894 T PT93303894 T PT 93303894T PT 575054 E PT575054 E PT 575054E
Authority
PT
Portugal
Prior art keywords
derivatives
human protein
protein derivatives
producing
high activity
Prior art date
Application number
PT93303894T
Other languages
English (en)
Inventor
Bruce Edward Gerlitz
Brian William Grinnell
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PT575054E publication Critical patent/PT575054E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6464Protein C (3.4.21.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21069Protein C activated (3.4.21.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
PT93303894T 1992-05-21 1993-05-19 Derivados de proteina c PT575054E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88719192A 1992-05-21 1992-05-21

Publications (1)

Publication Number Publication Date
PT575054E true PT575054E (pt) 2005-03-31

Family

ID=25390640

Family Applications (1)

Application Number Title Priority Date Filing Date
PT93303894T PT575054E (pt) 1992-05-21 1993-05-19 Derivados de proteina c

Country Status (23)

Country Link
US (1) US5453373A (pt)
EP (1) EP0575054B1 (pt)
JP (1) JP3564150B2 (pt)
KR (1) KR100291529B1 (pt)
CN (1) CN1080658A (pt)
AT (1) ATE286121T1 (pt)
AU (1) AU661901B2 (pt)
BR (1) BR9301944A (pt)
CA (1) CA2096604C (pt)
CZ (1) CZ286016B6 (pt)
DE (1) DE69333727T2 (pt)
DK (1) DK0575054T3 (pt)
ES (1) ES2233925T3 (pt)
FI (1) FI932282A (pt)
HU (1) HU218408B (pt)
IL (1) IL105757A0 (pt)
MX (1) MX9302917A (pt)
MY (1) MY110664A (pt)
NO (1) NO311299B1 (pt)
NZ (1) NZ247651A (pt)
PH (1) PH29911A (pt)
PT (1) PT575054E (pt)
RU (1) RU2122004C1 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2067525C (en) * 1991-05-09 1998-09-15 Helmut G. Alt Organometallic fluorenyl compounds, preparation and use
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
US5716795A (en) * 1991-10-04 1998-02-10 Matschiner; John T. Thrombomodulin-based coagulometric assay of the protein C system
AU2870992A (en) * 1991-10-04 1993-05-03 Board Of Regents Of The University Of Nebraska, The A soluble thrombomodulin-based one-stage assay for vitamin k-dependent coagulation-inhibiting proteins
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
HU224826B1 (en) 1997-04-28 2006-02-28 Lilly Co Eli Activated protein c formulations
ZA984698B (en) * 1997-06-05 2000-02-01 Lilly Co Eli Methods for treating thombotic disorders.
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
JP2003506006A (ja) * 1998-07-31 2003-02-18 イーライ・リリー・アンド・カンパニー 活性化プロテインcの寒冷顆粒化
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
CN1324244A (zh) 1998-10-22 2001-11-28 伊莱利利公司 治疗脓毒症的方法
CA2351067A1 (en) 1998-11-13 2000-05-25 Eli Lilly And Company Method of treating heparin-induced thrombocytopenia
ES2195655T3 (es) 1998-11-20 2003-12-01 Lilly Co Eli Procedimiento para tratar fiebre hemorragica virica con proteina c.
BR9915572A (pt) 1998-11-23 2001-08-14 Lilly Co Eli Processo de tratamento de doença de célula falciforme e talassemia
US6998122B1 (en) * 1999-04-30 2006-02-14 Eli Lilly And Company Protein C derivatives
JP2003514545A (ja) * 1999-11-19 2003-04-22 イーライ・リリー・アンド・カンパニー プロテインc誘導体
ES2234807T3 (es) * 2000-02-02 2005-07-01 Eli Lilly And Company Derivados de proteina c.
EP1263943A1 (en) * 2000-02-11 2002-12-11 Eli Lilly & Company Protein c derivatives
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
KR20030060915A (ko) * 2000-10-18 2003-07-16 맥시겐 에이피에스 단백질 씨 또는 활성 단백질 씨-유사 분자
IL154999A0 (en) * 2000-10-18 2003-10-31 Maxygen Aps Protein c or activated protein c-like molecules
US20040198652A1 (en) * 2001-04-24 2004-10-07 Carter J. Paul Methods and compositions for preventing and treating septic shock and endotoxemia
AU2003213146A1 (en) * 2002-03-08 2003-09-22 Eli Lilly And Company Activated protein c formulations
WO2003106666A2 (en) * 2002-06-14 2003-12-24 Maxygen Aps Protein c variants with altered properties
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
WO2006014839A2 (en) * 2004-07-23 2006-02-09 The University Of Rochester Activated protein c inhibits undesirable effects of plasminogen activator in the brain
EP1913155A4 (en) * 2005-06-23 2009-08-12 Univ British Columbia COAGULATION FACTOR III POLYMORPHISMS ASSOCIATED WITH PREDICTION RELATING TO THE RESULTS AND RESPONSE OF A SUBJECT TO THERAPY
EP2041338A4 (en) * 2006-06-09 2009-09-30 Univ British Columbia INTERFERON GAMMA POLYMORPHISMS AS INDICATORS OF PATIENT RESULTS IN FATIGUE PATIENTS
EP2178556B1 (en) * 2007-06-18 2011-08-17 Oregon Health & Science University Protein c for use in maintaining hemostasis
US20110171200A1 (en) * 2008-01-15 2011-07-14 Walley Keith R Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
CN104262479A (zh) 2008-12-19 2015-01-07 国家健康与医学研究院 丝氨酸蛋白酶衍生物及其在凝血功能障碍的预防或治疗中的用途
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
US20150150954A1 (en) 2012-07-04 2015-06-04 The University Of Sydney Treatment of inflammatory skin disorders
DK3137102T3 (da) 2014-04-16 2021-10-11 Zz Biotech Llc Apc til anvendelse til behandling af unormal kutan ardannelse
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
ZA889497B (en) * 1987-12-28 1990-08-29 Lilly Co Eli Vectors and compounds for expression of zymogen forms of human protein c
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5270178A (en) * 1990-02-23 1993-12-14 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
IL97311A0 (en) * 1990-02-23 1992-05-25 Lilly Co Eli Vectors and compounds for expression of glycosylation mutants of human protein c

Also Published As

Publication number Publication date
AU3869993A (en) 1993-11-25
CZ286016B6 (cs) 1999-12-15
NZ247651A (en) 1995-03-28
PH29911A (en) 1996-09-16
CN1080658A (zh) 1994-01-12
MX9302917A (es) 1993-11-01
DK0575054T3 (da) 2005-04-25
JPH0680698A (ja) 1994-03-22
KR930023370A (ko) 1993-12-18
RU2122004C1 (ru) 1998-11-20
NO931840D0 (no) 1993-05-19
NO311299B1 (no) 2001-11-12
EP0575054A3 (en) 1995-04-19
FI932282A0 (fi) 1993-05-19
ATE286121T1 (de) 2005-01-15
MY110664A (en) 1999-01-30
CZ94893A3 (en) 1994-01-19
NO931840L (no) 1993-11-22
EP0575054B1 (en) 2004-12-29
US5453373A (en) 1995-09-26
DE69333727D1 (de) 2005-02-03
EP0575054A2 (en) 1993-12-22
CA2096604A1 (en) 1993-11-22
HU218408B (hu) 2000-08-28
ES2233925T3 (es) 2005-06-16
DE69333727T2 (de) 2005-12-15
HUT69615A (en) 1995-09-28
HU9301461D0 (en) 1993-09-28
KR100291529B1 (ko) 2001-06-01
CA2096604C (en) 2003-12-16
BR9301944A (pt) 1993-11-30
AU661901B2 (en) 1995-08-10
JP3564150B2 (ja) 2004-09-08
FI932282A (fi) 1993-11-22
IL105757A0 (en) 1993-09-22

Similar Documents

Publication Publication Date Title
PT575054E (pt) Derivados de proteina c
NO900770L (no) Produksjon av glykoseoksidase i rekombinante systemer.
DE69514342T2 (de) Modifizierte polypeptide mit erhoehter biologischer aktivitaet
ES2087056T3 (es) 2-pirimidinaminas sustituidas en las posiciones 4, 5 y 6.
YU31891A (sh) Vektori i jedinjenja za ekspresiju mutanata glikozilovanja humanog proteina c
DE69033756T2 (de) Gene, die für MACIF Proteine kodieren, Expressionsvektoren mit diesem Genen, und Transformantenzellen mit diesem Proteinen
DE3882611T2 (de) Menschliches Interleukin-4, Expressionsvektoren dafür und diese enthaltende Transformanten.
MX9202871A (es) 5-(amino substituidas)-8-(fenil substituidas)-3h,6h-1,4,5a,8a-tetraazaacenaf-tilen-3-onas.
DE68924022T2 (de) Protein mit hemmender Aktivität gegenüber menschlichem Plasmin.
DE29614891U1 (de) Stützelement
DE3862073D1 (de) Tetramethyl-cis-diaza-bicyclo(4.2.0.)oktan-3,5-dion-derivate mit differentiationsinduzierender aktivitaet.
ITRM930343A0 (it) Proteine ricombinanti, vettori per l'espressione e loro usi.
MX9203129A (es) Proteinas bmp-5.
FI950779A (fi) Homepromoottorit, jotka ovat aktiivisia glukoosin läsnäollessa